New drug combo shows promise against tough head and neck cancer
NCT ID NCT05213884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment plan for people with advanced head and neck cancer that cannot be removed by surgery. The plan combined the immunotherapy drug camrelizumab with chemotherapy and radiation. 39 adults took part. The goal was to see if the treatment could help control the cancer and how safe it was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Chongqing University Three Gorges Hospital
Wanzhou, Chongqing Municipality, 404100, China
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, 646000, China